Physician profile
Gregory L Stamper
NPI 1790765592
$4,901.16
in general payments reported to CMS, 2019-2025
31 companies · $86.32 in 2025
The $86.32 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $807 · 2021: $1,036 · 2022: $1,052 · 2023: $988 · 2024: $92.64 · 2025: $86.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $859.15 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $515.63 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $499.75 | 2019-2023 | Breztri, Farxiga |
| Pfizer INC. | $383.54 | 2019-2025 | |
| Novo Nordisk INC | $382.45 | 2019-2023 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $357.01 | 2019-2023 | Fanapt, Hetlioz |
| Sanofi-Aventis U.S. LLC | $338.70 | 2019-2022 | |
| Abbvie INC. | $319.79 | 2019-2023 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.00 | 2020-2023 | Jardiance |
| Gilead Sciences, INC. | $153.96 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $151.44 | 2019-2021 | |
| Amarin Pharma, INC. | $86.41 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $80.05 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $73.27 | 2019-2022 | |
| Astellas Pharma US INC | $49.25 | 2020-2023 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.05 | 2022 | |
| Xeris Pharmaceuticals, INC. | $47.63 | 2021 | |
| Avanir Pharmaceuticals, INC. | $39.52 | 2019 | |
| Abbott Laboratories | $37.04 | 2021-2023 | Freestyle Libre 2 |
| Jazz Pharmaceuticals INC. | $36.32 | 2021 | |
| Sanofi Pasteur INC. | $27.69 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $24.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.13 | 2021 | |
| Idorsia Pharmaceuticals US INC | $20.28 | 2022 | |
| Mylan Specialty L.P. | $19.62 | 2019 | |
| Exact Sciences Corporation | $19.49 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $18.14 | 2021 | |
| Insulet Corporation | $17.87 | 2022 | |
| Horizon Therapeutics Plc | $17.25 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.61 | 2021 | |
| Avion Pharmaceuticals | $11.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Stamper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.